“Our biologics license application (BLA) for our ATEV in vascular trauma remains under review by the U.S. Food and Drug Administration (FDA),” said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte (HUMA). “FDA leadership has not provided us a timeline for the completion of their review. As noted in our previous announcements, during the course of the BLA review the FDA conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing, including post-marketing and labeling discussions. Based on these interactions, we remain confident in the approvability of the ATEV in treating vascular trauma.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte price target raised to $12 from $6 at H.C. Wainwright
- Humacyte announces reuslts from V007 Phase 3 trial of ATEV in AV
- Humacyte to host KOL event on he use of ATEV for AV access in hemodialysis
- Hertz Global Holdings call volume above normal and directionally bullish
- Unusually active option classes on open October 18th